Gat Sajid Shah

The backbone of @Injective ’s RWA offering is its iAssets framework and an on-chain central limit order book (CLOB), combined with robust oracle price feeds and shared liquidity provided by market makers.

Unlike traditional “spot tokenization,” where real-world assets are held in a custodian or SPV and then wrapped into tokens (with all the attendant custody, regulation, counterparty, and compliance risks), Injective’s iAssets are synthetic derivatives. That means you don’t actually own the underlying asset — rather, you hold a contract that mirrors its price.

Practically, this offers several advantages:

Capital efficiency — traders can gain large exposure (e.g., $100,000 equivalent of a stock) using a fraction of capital as margin (e.g., a few thousand USD) thanks to leverage.

24/7 access — unlike traditional markets that trade only during market hours, #injective ’s perpetuals trade around the clock.

No custody of real assets — since there’s no need to hold the actual stocks, commodities or other asset classes, regulatory and operational overheads are reduced.

For example: equities tied to the so-called “Magnificent 7” — the top large-cap tech stocks — reportedly generated a large portion of the volume (roughly 42.6%, about US$2.4 billion) in the total RWA volume. Other categories such as digital-asset treasuries and pre-IPO companies have also begun to show activity.

Injective’s approach — relying on oracles + synthetic derivatives instead of actual asset custody — effectively “bridges” traditional financial markets with decentralized finance (DeFi). For many traders, this means access to global equities, commodities or even private-company exposure without needing brokerage accounts, geographic restrictions, or minimum investment thresholds.
$INJ
{spot}(INJUSDT)